Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 16/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 11/20 | 0.39 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | RAF1 | P04049 | 1/20 | 0.37 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1309533 | 0.78 | PIK3CA (0.52) | PIK3CAPIK3R1MTORPIK3CDPIK3CG | |
| SCHEMBL29300852 | 0.75 | PRKDC (0.44) | PRKDCPIK3CAAKT1CYP1A2MAPT | |
| SCHEMBL14923636 | 0.75 | KCNQ3 (0.44) | PRKDCAKT1CYP1A2MAPTCYP2C19 | |
| SCHEMBL29215163 | 0.74 | PRKDC (0.44) | PRKDCPIK3R1MTORCYP1A2MAPT | |
| SCHEMBL29301634 | 0.73 | MAPT (0.61) | PRKDCMTORCYP1A2MAPTCYP2C19 | |
| SCHEMBL252383 | 0.73 | BTK (0.47) | PIK3CAPIK3R1AKT1MTORPIK3CD | |
| SCHEMBL246130 | 0.72 | LRRK2 (0.50) | PIK3CAMTORPIK3CDPIK3CBCYP2C19 | |
| SCHEMBL247209 | 0.72 | LRRK2 (0.43) | PIK3CAPIK3R1MTORCYP2C19 | |
| SCHEMBL15461818 | 0.71 | PIK3CA (0.54) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL15461816 | 0.71 | PIK3CA (0.54) | PIK3CAMTORPIK3CDPIK3CBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2588471-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | Amgen Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2012003283-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | PRKDC 30/4885PIK3CA 28/4885PIK3R1 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.